Impact biomedical announces license agreement with prophase labs to produce and distribute viral-fighting compound equivir

Henrietta, n.y., june 28, 2022 (globe newswire) -- impact biomedical, inc., a wholly owned subsidiary of dss, inc. (nyse american: dss), along with its scientific research partner global research and discovery group sciences (grdg), announced today that it signed a license agreement with prophase labs (nasdaq: prph) for equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.
DSS Ratings Summary
DSS Quant Ranking